- Home
- KNOP vs MREO Comparison
KNOP vs MREO Comparison
Compare KNOP & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KNOP | MREO |
|---|---|---|
| Founded | 2013 | 2015 |
| Country | United Kingdom | United Kingdom |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 366.5M | 324.6M |
| IPO Year | 2013 | N/A |
Fundamental Metrics
Financial Performance| Metric | KNOP | MREO |
|---|---|---|
| Price | $10.48 | $0.57 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 6 |
| Target Price | N/A | ★ $3.90 |
| AVG Volume (30 Days) | 109.6K | ★ 37.3M |
| Earning Date | 12-04-2025 | 11-10-2025 |
| Dividend Yield | ★ 1.00% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.17 | N/A |
| Revenue | ★ $352,712,000.00 | $500,000.00 |
| Revenue This Year | $14.84 | N/A |
| Revenue Next Year | $1.98 | $6,363.05 |
| P/E Ratio | $8.90 | ★ N/A |
| Revenue Growth | ★ 17.65 | N/A |
| 52 Week Low | $5.29 | $0.20 |
| 52 Week High | $11.10 | $3.26 |
Technical Indicators
Market Signals| Indicator | KNOP | MREO |
|---|---|---|
| Relative Strength Index (RSI) | 52.02 | 33.96 |
| Support Level | $10.06 | $0.51 |
| Resistance Level | $11.10 | $0.78 |
| Average True Range (ATR) | 0.27 | 0.10 |
| MACD | -0.01 | 0.02 |
| Stochastic Oscillator | 40.38 | 59.10 |
Price Performance
Historical ComparisonAbout KNOP KNOT Offshore Partners LP
KNOT Offshore Partners LP owns, operates, and shuttles tankers under long-term charters in the North Sea and Brazil. The company provides crude oil loading, transportation, and storage services under time charters and bareboat charters. The Partnership is formed for acquiring ownership interests in over four shuttle tankers owned by Knutsen NYK Offshore Tankers AS (KNOT). It operates through the shuttle tanker market segment.
About MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).